The cardiovascular safety of diabetes drugs–insights from the rosiglitazone experience
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Related articles
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SUs, in contrast, may be problematic when used in combinations because they can cause hypoglycemia and may reduce, eliminate, or minimize the weight-loss benefit of drugs such as metformin, GLP-1 RAs, and SGLT2is.993”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [993]
Citations
Cites
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60953-3 · Cited by 1,393
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
Is There Clear and Convincing Evidence of Cardiovascular Risk with Rosiglitazone?
Kaul, S., & Diamond, G. A. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.65 · Cited by 8
Self-citation
Cited by
Items 101–200 of 201
Shin, S., & Kim, H. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s105285 · Cited by 12
“The paucity of data on long-term CV risk with OAs is attributable to the conventional drug approval process set forth by the FDA, which was solely based on the effect of an agent on surrogate end points, such as serum glucose and HbA 1c reduction.(28) As a result, evaluation of more clinically relevant outcomes, such…”
Cardiovascular Safety of New Drugs for Diabetes: Getting the Balance Right?
Krentz, A. J., & Hompesch, M. (2014) · Pharmaceutical Medicine · doi:10.1007/s40290-014-0053-7 · Cited by 10
“In response to the results of SAVOR and EXAMINE, there have been calls for a more targeted assessment of cardiovascular safety of new diabetes drugs [12].”
ResultInfluentialFurtado, R. H. M., Venkateswaran, R. V., Nicolau, J. C., Gurmu, Y., Bhatt, D. L., Storey, R. F., Steg, P. G., Magnani, G., Goto, S., Dellborg, M., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015785 · Cited by 9
“29 The limb outcomes, although not significantly lower, were directionally consistent with overall MACE and MI reductions.”
Botana, M., Escalada, J., Merchante, Á., Reyes‐García, R., & Rozas, P. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01277-1 · Cited by 11
“However, after the rosiglitazone controversy [18] and the discovery that oral hypoglycemic drugs can maintain a normal blood glucose level but paradoxically increase CV events in patients with T2D [19], in 2008 the FDA issued a guidance for industry to include CV safety as an endpoint for all novel antihyperglycemic m…”
BackgroundCardiovascular Outcomes of New Medications for Type 2 Diabetes
Trujillo, J. M., Wettergreen, S. A., Nuffer, W. A., Ellis, S. L., & McDermott, M. T. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0295 · Cited by 8
Gera, A., Latif, F., Borra, V., Naz, S., Mittal, V., Ayoobkhan, F. S., Kumar, T., Wajid, Z., Deb, N., Prasad, T., et al. (2025) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2025.101638 · Cited by 20
“These drugs are recognized for their capacity to mitigate TNF-α -induced oxidative stress and inflammation in endothelial cells through mechanisms involving calcium and AMPK [28,29].”
Comparing Diabetes Medications
Lipska, K. J., & Krumholz, H. M. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.13433 · Cited by 8
Systematic Reviews to Ascertain the Safety of Diabetes Medications
Gionfriddo, M. R., Morey‐Vargas, O. L., Brito, J. P., Leppin, A. L., Murad, M. H., & Montori, V. M. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0478-0 · Cited by 9
Rawson, N. S. B. (2014) · PubMed · Cited by 8
Flory, J., Ukena, J., & Floyd, J. S. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0633-y · Cited by 9
Turner, J. R. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1300252 · Cited by 9
Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?
Rhee, E. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.304 · Cited by 12
“Food and Drug Administration (FDA) has requested that results from a cardiovascular (CV) safety trial should be submitted for all new anti-diabetic medications that come to the market [7].”
BackgroundJankowska, A., Wesołowska, A., Pawłowski, M., & Chłoń‐Rzepa, G. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666191011144818 · Cited by 8
Kim, J.-Y., Yang, S., Lee, J. I., & Chang, M. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153502 · Cited by 7
“A recent perspective article published in New England Journal of Medicine by the US Food and Drug Administration (FDA) advisory committee members stated that the optimal approach to the reduction of cardiovascular risk in diabetes patients should focus on the management of standard cardiovascular risk factors rather t…”
BackgroundCao, X., Mao, M., Diao, J., Hou, Y., Hong, S., Gan, Y., Li, J., Tong, X., Wu, C., Zuo, Z., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.683156 · Cited by 8
“Although careful safety evaluations demonstrated that rosiglitazone was with no increased risk of heart attack compared to the standard T2DM medicines metformin and sulfonylurea, great concerns remained as to the potential side effects of classical TZDs (Consoli and Formoso, 2013; Hiatt et al., 2013; Goltsman et al.,…”
BackgroundInfluentialEvidence-based estimation of insulin resistance
Petrie, J. R. (2014) · Diabetologia · doi:10.1007/s00125-014-3322-9 · Cited by 7
“The advent of thiazolidinedione ‘insulin sensitisers’ provided an intense stimulus to research in the 1990s, but this was short-lived owing to a protracted period of uncertainty over safety [1].”
BackgroundExtrarenal Benefits of SGLT2 Inhibitors in the Treatment of Cardiomyopathies
Yerra, V. G., & Connelly, K. A. (2024) · Physiology · doi:10.1152/physiol.00008.2024 · Cited by 7
Overdiagnosis and overtreatment over time
Martin, S. A., Podolsky, S., & Greene, J. (2015) · Diagnosis · doi:10.1515/dx-2014-0072 · Cited by 3
“Debate over the proper public health calibration of the ideal HbA1c also persists, as does the cost-benefit of enrolling populations with borderline glucose metabolism into regimens of long-term pharmacotherapy [19].”
BackgroundKorytkowski, M. T., Karslioglu French, E., Brooks, M., DeAlmeida, D., Kanter, J., Lombardero, M., Magaji, V., Orchard, T., & Siminerio, L. (2016) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000206 · Cited by 6
“prior to seeking approval for clinical use.(13) CVD end points and mortality are also used as a critical factor in ongoing surveillance of existing glucose-lowering therapies.”
Lambadiari, V., Dimitriadis, G., & Kadoglou, N. P. E. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9690-3 · Cited by 6
“The notorious adverse events of rosiglitazone on cardiovascular safety reinforced an important change in FDA policy in 2008, resulting in numerous trials involving novel anti-diabetic agents to prove cardiovascular safety [41].”
BackgroundYami, M. S. A., Alfayez, O. M., & Alsheikh, R. (2018) · Heart Lung and Circulation · doi:10.1016/j.hlc.2018.03.018 · Cited by 6
Cai, X., & Ji, L. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01079-x · Cited by 6
Targeting Hyperglycaemia with Anti-Obesity Drugs: Time for a Paradigm Shift?
Krentz, A. J., & Hompesch, M. (2013) · Drugs · doi:10.1007/s40265-013-0123-2 · Cited by 6
“Regulatory authorities became highly sensitized to the risk-to-benefit ratios of new glucose-lowering drugs in the wake of the rosiglitazone debacle [21, 22].”
BackgroundCausal Pluralism in Medicine and its Implications for Clinical Practice
Maziarz, M. (2023) · Journal for General Philosophy of Science · doi:10.1007/s10838-023-09658-1 · Cited by 5
“Later research showed the inferiority of the rosiglitazone treatment (Hiatt et al. 2013), and therefore we focus on this secondary outcome instead of the overall comparison of deaths and hospitalizations caused by all cardiovascular causes.”
Tang, H., & Chen, C. Y. (2014) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2014/385120 · Cited by 5
“Thiazolidinediones are the notorious representatives [28, 29].”
Fleming, G. A. (2014) · Springer eBooks · doi:10.1007/978-1-4471-4920-0_12 · Cited by 5
“This requirement was put in place less than a year after an advisory committee was called to review evidence that rosiglitazone treatment was associated with an increased cardiovascular risk [ 6 ].”
BackgroundKudva, Y. C., & Nair, K. S. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.11.016 · Cited by 5
Han, Y., Kwon, S. Y., Kim, J., Na, C. J., Choi, S., Min, J., Bom, H., Kim, Y., Oh, I., Chae, H., et al. (2015) · EJNMMI Research · doi:10.1186/s13550-015-0128-9 · Cited by 7
“In 2010, the FDA took a cautious stance and limited exposure to rosiglitazone [30].”
BackgroundPotential Cardiovascular Effects of the Glucagon-like Peptide-1 Receptor Agonists
CHILTON, R. J. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000483 · Cited by 5
“Overall, the DURATION and LEAD studies collectively support that exenatide once weekly and liraglutide confer SBP reductions from baseline, glucose-lowering agents do not increase cardiovascular risk, and the ability to produce positive cardiovascular effects beyond those afforded by glucose control would be optimal […”
ResultMethods for Quantifying Insulin Sensitivity and Determining Insulin Time-Action Profiles
Krentz, A. J., Heinemann, L., & Hompesch, M. (2014) · Springer eBooks · doi:10.1007/978-1-4471-4920-0_1 · Cited by 6
Wang, H., Liu, J., & Zhao, H. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s53048 · Cited by 3
“19,20 However, the results from Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome (EXAMINE) study showed that the rates of the major adverse cardiovascular events were not increased with alogliptin as compared with placebo in T2DM patients with…”
Mijajlovic, M. D., Bornstein, N. M., & Aleksić, V. (2025) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864251326769 · Cited by 4
Halimi, S. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30265-0 · Cited by 3
Goyat, R., Rai, P., Chang, J., Ponte, C. D., & Tan, X. (2018) · Clinical Drug Investigation · doi:10.1007/s40261-018-0639-z · Cited by 3
“For example, rosiglitazone users were observed to have a higher risk of heart attacks, strokes, and CV mortality [19].”
Quantification of Insulin Action in Human Subjects
Krentz, A. J., Weyer, C., & Hompesch, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-11748-1_1 · Cited by 6
Uwabagira, N., Sarojini, B. K., & Prabhu, A. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200424102615 · Cited by 3
Luft, F. C. (2020) · Acta Physiologica · doi:10.1111/apha.13589 · Cited by 4
Agarwal, S., Parashar, A., & Menon, V. (2014) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(14)61335-8 · Cited by 3
Faster drug approval: challenges for safety
Preziosi, P. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1194825 · Cited by 3
“↑ [81] Cardiac heart failure ↑ 170–649 more cases than pioglitazone [81–83] Death as a result of cardiovascular causes ↑ 431 cases more than pioglitazone [82] EXPERT OPINION ON DRUG SAFETY 1213”
BackgroundChai, B. K., LAU, Y. S., Loong, B. J., RAIS, M. M., Ting, K., DHARMANI, D. M., & Mohankumar, S. K. (2018) · Physiological Research · doi:10.33549/physiolres.933706 · Cited by 4
“The use of these glitazones, including rosiglitazone, have been cautioned for increased risk of cardiovascular diseases in T2DM patients (Hiatt et al. 2013, Nissen and Wolski 2007, Nissen and Wolski 2010).”
BackgroundSmall, A. M., & Wiviott, S. D. (2024) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.24.06600-6 · Cited by 3
Braconi, L., Mattolini, L., Romanelli, M. N., Teodori, E., & Manetti, D. (2026) · Biomolecules · doi:10.3390/biom16071058 · Cited by 2
“Although the clinical use of some TZDs has been limited by safety concerns, their pharmacophoric relevance has stimulated interest in their repurposing and structural modification [72].”
Rajput, R., Mukherjee, J. J., Ayyar, V. S., & Ghosal, S. (2018) · Clinical Diabetology · doi:10.5603/dk.2018.0024 · Cited by 2
“However, despite their simplicity in design, many primary care physicians, and the occasional expert, misinterpret glycaemic efficacy trials as CVOTs [17, 19].”
BackgroundInfluentialSymptomatic chronic obstructive pulmonary disease in clinical trials and in a population-based study
Niederseer, D., Richter, S. A. M., Neunhäeuserer, D., Lamprecht, B., Buist, S. A., Studnicka, M., & Niebauer, J. (2014) · Sleep And Breathing · doi:10.1007/s11325-014-1087-5 · Cited by 2
Turner, J. R., Karnad, D. R., & Kothari, S. (2016) · Springer eBooks · doi:10.1007/978-3-319-40347-2_12 · Cited by 2
Furtado, R. H. M., Silva, P. G. M. B. E., Fonseca, H. A. R., Neto, A. S., Corrêa, T. D., Guimarães, H. P., Pereira, A. J., Olivato, G. B., Zampieri, F. G., Lisboa, T. C., et al. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.11.069 · Cited by 2
Scotina, A. D., Zullo, A. R., Smith, R. J., & Gutman, R. (2020) · Statistical Methods in Medical Research · doi:10.1177/0962280220928109 · Cited by 2
“us and potentially fatal complication of the disease, the choices 17 of treatments are highly complex [59], and the eects of various antihyperglycemic treatments on macrovascular events is uncertain [60,61]. The analysis presented here is a novel approach to comparing the risks of major adverse cardiovascular events (…”
BackgroundSelf-citationThe Effects of Ranolazine on Hemoglobin A1c in a Veteran Population.
Greiner, L., Hurren, K. M., & Brenner, M. J. (2018) · Europe PMC (PubMed Central) · Cited by 2
New oral hypoglycaemics fail to show cardiovascular benefits
Cohen, D. R. (2013) · BMJ · doi:10.1136/bmj.f5458 · Cited by 2
Rosiglitazone, medical reversal, and back to basics for diabetes.
Prasad, V. K. (2014) · PubMed · Cited by 2
Relationship Between Glycemic Control and Cardiovascular Outcomes
Chowdhury, S. R., Tanzil, T., Chowdhury, R. H., & Alam, M. M. (2020) · Chattagram Maa-O-Shishu Hospital Medical College Journal · doi:10.3329/cmoshmcj.v19i2.50043 · Cited by 1
Marques, F., Valicelli, F. H., Tanaka, D. M., & Simões, M. V. (2024) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20240027 · Cited by 1
Early Phase Metabolic Research with Reference to Special Populations
Morrow, L., & Krentz, A. J. (2014) · Springer eBooks · doi:10.1007/978-1-4471-4920-0_9 · Cited by 1
What Are Current Main Obstacles to Reach Drug Approval?
Boudes, P. F. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-420246-7.00002-5 · Cited by 1
LEADER and the new ‘cardiovascular’ glucose‐lowering agents
Livingstone, R., Boyle, J. G., & Petrie, J. R. (2016) · Practical Diabetes · doi:10.1002/pdi.2033 · Cited by 1
Gysling, E. (2014) · pharma-kritik · doi:10.37667/pk.2014.925 · Cited by 1
Dipeptyl peptidase – 4 inhibitors in type 2 diabetes: Cardiovascular risk reduction?
Zarowitz, B. J. M. (2013) · Geriatric Nursing · doi:10.1016/j.gerinurse.2013.10.002 · Cited by 1
Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes
Steinberg, H. O. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1168687 · Cited by 2
“the CV risk associated with the latter [16] and, conversely, use of placebo controls may lead to imbalances in background therapy that might influence CV outcomes.[16]”
BackgroundInfluentialShahady, E. J., & Leahy, J. L. (2018) · Clinical Diabetes · doi:10.2337/cd18-0064 · Cited by 4
“Food and Drug Administration (FDA) advisory committee reviews, a boxed warning for myocardial ischemia was added to the rosiglitazone prescribing information, and access to rosiglitazone was restricted (16).”
BackgroundWeighing the Benefits and Risks of Diabetes Drugs: A Call for a Unified Global Approach
Lau, D. C. W. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.12.002 · Cited by 1
Erwiderung auf den Leserbrief zum Beitrag: „Testosteronmangel im Alter – was ist zu tun“
Jaschke, N., Rachner, T. D., & Hofbauer, L. C. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1423-2691 · Cited by 1
Antidiabetika bei Patienten mit Niereninsuffizienz
Czock, D. (2014) · Der Nephrologe · doi:10.1007/s11560-014-0879-8
Human in vivo studies on the non-glycaemic effects of thiazolidinedione derivatives
Rennings, A. J. M. (2014) · Radboud Repository (Radboud University)
Ududec, O. A., Vujanovic, S., & Kénol-Maurrasse, R. (2015) · Pharmactuel
Response to Hitman. Insulin degludec: a new insulin for today?
Schmidt, T. A. (2013) · Diabetic Medicine · doi:10.1111/dme.12375
Treatments for Type 2 Diabetes; a Focus on DPP4 Inhibitors
TOMKIN, G. H. (2014) · Pharmaceutical Regulatory Affairs Open Access · doi:10.4172/2167-7689.1000114
“The cardiovascular safety of diabetic drugs continues to raise concern [43].”
BackgroundHalimi, S. (2014) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(14)70791-6
“Après « l’affaire rosiglitazone », en 2008 [2], quoique les conclusions en aient été reconsidérées depuis [3, 4], la Food and Drug Administration (FDA) des États-Unis a édicté, dans un guide destiné à l’industrie, les critères de sécurité cardiovasculaire auxquels doivent répondre tout nouvel antidiabétique (oral ou i…”
New Diabetes Drugs: Ready for Prime Time?
Horowitz, K. R. (2014)
Kardiovaskuläre Effekte von Antidiabetika
Drexel, H., & Scherbaum, W. A. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0089-2
“Mittlerweile wurden diese möglichen negativen Auswirkungen von Rosiglitazon durch neuere Daten relativiert, das berichtete erhöhte Risiko für kardiovaskuläre Ereignisse unter dieser Substanz veranlasste jedoch die amerikanische Arzneimittelbehörde dazu, für alle neuen Antidiabetika den Nachweis der kardiovaskulären Si…”
BackgroundIschemic Heart Disease in Diabetes
Saely, C. H., Vathie, K., & Drexel, H. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch44
Krentz, A. J., & Sinclair, A. J. (2017) · Wiley eBooks · doi:10.1002/9781118954621.ch21
Avandia: Cardiovascular Safety Concern Remains
Jiang, C. L. (2015) · Journal of Molecular Biomarkers & Diagnosis · doi:10.4172/2155-9929.1000258
“A recent article in New England Journal Medicine concluded: “From a cardiovascular perspective, rosiglitazone, saxagliptin, and alogliptin appear to be relatively safe [1].”
BackgroundMethodCardiovascular safety of oral antidiabetic therapy in type 2 diabetes mellitus- review article
Singh, P., Yadav, S. K., Sharma, H., & Kumar, M. T. (2017) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20171805
“This benefit was sustainable, with persistent risk reduction observed in the metformin group for any diabetes related endpoint.(5) A meta-analysis of randomized trial showed that metformin reduced adverse”
BackgroundDiagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes
Cusi, K. J. (2017) · Contemporary diabetes · doi:10.1007/978-3-319-61013-9_4
Goyat, R., Thornton, J. D., Tan, X., & Kelley, G. A. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-017644
Noninferiority studies: Not inherently unethical
McCarren, M., & Semla, T. P. (2018) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp180052
Fleming, G. A., & Harvey, B. E. (2019) · Springer eBooks · doi:10.1007/978-3-030-11748-1_19 · Cited by 1
Petrie, J. R., & Salt, I. P. (2019) · Springer eBooks · doi:10.1007/978-3-030-16481-2_40
Baker, H. E. (2020) · IUScholarWorks (Indiana University) · doi:10.7912/c2/2031
Wilkinson, S. (2020) · LSHTM Research Online (London School of Hygiene and Tropical Medicine) · doi:10.17037/pubs.04656434
The role of apoptosis during inflammation resolution in Lyme arthritis
Hilliard, K. A. (2019) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/75021
Dipeptidyl Peptidase 4 Inhibitor, an Update
Lee, J. H. (2021) · Journal of Korean Diabetes · doi:10.4093/jkd.2021.22.2.91
Pashkova, E. Y. (2022) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2022-11-1-65-72
Early Phase Metabolic Research with Reference to Special Populations
Morrow, L., & Krentz, A. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-11748-1_20
(2019) · PeerJ · doi:10.7287/peerj.7815v0.2/reviews/1
“91 Rosiglitazone (RSG) is a kind of peroxisome proliferator-activated receptor-gamma (PPAR-γ) 92 agonist, commonly used to treat type 2 diabetes mellitus (T2DM), which could enhance insulin 93 sensitivity (Hiatt et al., 2013).”
BackgroundIschaemic Heart Disease in Diabetes
Lehrke, M., & Marx, N. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch49
Evidenzbasierte Therapie von Hyperphosphatämie und Vitamin-D-Mangel
Heine, G. H. (2024) · Nephrologie aktuell · doi:10.1055/a-2415-9576
Yang, Z., Jiao, Y., Sun, Y., Wu, Y., Xu, L., Zhang, J., Yu, L., Shen, P., Lin, H., Shui, L., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70564
“26,27 However, such trials are lacking for older drugs like metformin and sulfonylurea, both widely prescribed since the mid-20th century.”
Natural compounds magnolol and dicoumarol enhance adipogenesis for future food applicationsPreprint
Xie, Q., Kawecki, N. S., Chen, K. K., Cohen, C. A., Cheng, E., Blencowe, M., Yang, X., Damoiseaux, R. D., & Rowat, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.06.736869
“…proliferator-activated receptor gamma (PPAR ), which is a master regulator of adipogenesis 12 , with the pharmaceutical rosiglitazone acting as a direct PPAR γ agonist; however, synthetic inducers carry regulatory and safety limitations that constrain their use in food applications 13,14 .”
Metadata
- Authors
- Hiatt, W. R., Kaul, S., & Smith, R. J.
- Affiliations
- University of Colorado Anschutz (US)
- Cedars-Sinai Medical Center (US)
- Brown University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-03
- Volume
- 369
- Issue
- 14
- Pages
- 1285-1287
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2329117883
- Cited by
- 204
- References
- 6
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 10 · 2023: 6 · 2022: 7 · 2021: 10 · 2020: 15 · 2019: 23 · 2018: 24 · 2017: 14 · 2016: 24 · 2015: 26 · 2014: 33 · 2013: 6
- FWCI
- 23.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- cardiovascular safety, diabetes drugs, rosiglitazone, thiazolidinediones, cardiovascular adverse events, drug safety
- MeSH terms
- Rosiglitazone, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Europe, Humans, Hypoglycemic Agents, Myocardial Infarction, United States, United States Food and Drug Administration, Drug Approval, Thiazolidinediones, Safety-Based Drug Withdrawals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.